**Referenca**

1. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020: doi:10.1093/eurheartj/ehaa612
2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–847.
3. Colilla S, Crow A, PetkunW, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142–1147.
4. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–953.
5. Lloyd-Jones DM,Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A,Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–1046.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–2375
7. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation
8. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–220.
9. Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013;44:3103–3108.
10. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015;4:e001486
11. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation 2012;126:e143–146.
12. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807–1824.
13. Kannel WB,Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N.
14. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013;167:2412–2420.
15. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S, RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014;129:1568–1576.
16. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O’Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the reallife global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–639.
17. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP,Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920–2925.
18. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520–526.
19. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–2486.
20. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154–162.
21. Benjamin EJ,Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946–952.
22. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359–364.
23. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J 2013;34:1061–1067.
24. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235–2243.
25. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.
26. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476–484.
27. Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2012;7:276–281.
28. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M,Weimar C, Kohrmann M,Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357–3364.
29. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316–321.
30. Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, HeindelW, Breithardt G, Berger K, Ringelstein EB, Kirchhof P,Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125–2132.
31. Ball J, Carrington MJ, Stewart S, SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart 2013;99:542–547.
32. Marzona I, O’Donnell M, Teo K, Gao P, Anderson C, Bosch J, Yusuf S. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ 2012;184:E329–336.
33. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.e1–19.
34. Von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, Ladwig KH. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis—data from the German Competence Network on Atrial Fibrillation. Europace 2015;17: 1354–1362.
35. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;167:735–742.e2.
36. Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. Management of patients wtih atrial fibrillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol 2014;37: 277–284.
37. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90: 286–292.
38. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. CircCardiovasc Qual Outcomes 2011;4:313–320.
39. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016;532:h7013.
40. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016;13:321–332.
41. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. Gender-related differences in risk of cardiovascular morbidit and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 9519 patients. Int J Cardiol 2014;177:91–99.
42. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study Circulation 2005;112:1687–1691.
43. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014;113:485–490.
44. Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC, Lip GY. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. Int J Cardiol 2012;161: 39–44
45. Ball J, Carrington MJ,Wood KA, Stewart S, SAFETY Investigators.Women versus men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). PLoS One 2013;8:e65795.
46. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complication in patients with atrial fibrillation: a systematic review. QJM 2007;100:599–607.
47. Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J, Delacretaz E, Tanner H. Gender differences in patients referred for atrial fibrillation managemen to a tertiary center. Pacing Clin Electrophysiol 2009;32:622–626.
48. Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V, Clementi F, Fagundes RL, Leo R, Romeo F, Mantica M. Gender-related differences in catheter ablation of atrial fibrillation. Europace 2007;9:613–620.
49. Henry L, Hunt S, Holmes SD, Martin LM, Ad N. Are there gender differences in outcomes after the Cox-Maze procedure for atrial fibrillation? Innovations (Phila) 2013;8:190–198.
50. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion results of the PAFAC trial. Eur Heart J 2004;25:1385–1394.
51. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C Kottkamp H. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112:307–313.
52. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J 2009;30:2969–2977c.
53. Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atria fibrillation: A systematic review of age/gender differences and cardiovascular outcomes Int J Cardiol 2015;191:172–177.
54. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4: 369–382.
55. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967–975.
56. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A Diaz R, Hohnloser SH, Lewis BS, Shestakovska O,Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–287a.
57. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015;36:288–296.
58. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP Bryan S, Davies M, Lip GY, Allan TF. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial BMJ 2007;335:383.
59. Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, Ringleb P, HackeW, Veltkamp R. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiograph for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012;43:2689–2694.
60. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O’Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK,Mamdani M, EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467–2477.
61. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013;15:135–140.
62. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76
63. January CT, Wann LS, Calkins H et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019;140:e125–e151.
64. Fauchier L, Philippart R, Clementy N et al. How to define valvular atrial fibrillation? Arch

Cardiovasc Dis 2015;108:530–53

1. Cresti A, Garcia-Fernandez MA, Miracapillo G et al. Frequency and significance of right atrial

appendage thrombi in patients with persistent atrial fibrillation or atrial flutter. J Am Soc

Echocardiogr 2014;27:1200–1207.

1. Jørgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen

Stroke Study. Stroke 1996;27:1765–1769.

1. Thygesen SK, Frost L, Eagle KA, Johnsen SP. Atrial fibrillation in patients with ischemic stroke: A

population-based study. Clin Epidemiol 2009;1:55–65.

1. Spieler JF, Lanoe JL, Amarenco P. Socioeconomic aspects of postacute care for patients with

brain infarction in France. Cerebrovasc Dis 2002;13:132–141.

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent

stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;

146:857–867.

1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ,

Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison

of the efficacy and safety of new oral anticoagulants with warfarin in patients

with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:

955–962.

1. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L,

Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP,

Boriani G. Prognosis and treatment of atrial fibrillation patients by European

1. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ,

Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries

after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary

results of the PREvention oF thromboemolic events—European Registry in Atrial

Fibrillation (PREFER in AF). Europace 2014;16:6–14.

1. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A,

Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of

the German Competence NETwork on Atrial Fibrillation: Patient characteristics

and initial management. Europace 2009;11:423–434.

1. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A,

Wegscheider K, Treszl A, Meinertz T, Oeff M, Ravens U, Breithardt G,

Steinbeck G. Impact of the type of centre on management of AF patients: surprising

evidence for differences in antithrombotic therapy decisions. Thromb Haemost

2011;105:1010–1023.

1. Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C,

Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B,

Diez AI, Gich I, Guyatt G. Values and preferences in oral anticoagulation in patients

with atrial fibrillation, physicians’ and patients’ perspectives: protocol for

a two-phase study. BMC Health Serv Res 2008;8:221.

1. Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, Blendea D,

Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P,

MD GC, Camm AJ. Contemporary management of atrial fibrillation: what can

clinical registries tell us about stroke prevention and current therapeutic approaches?

J Am Heart Assoc 2014;3:e001179.

1. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran

adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495–504.

1. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing

Stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:

590–592.

1. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–817.
2. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of Atrial

Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement Heart Rhythm 2015;12:e105–113.

1. Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J,

Zamorano JL, Kirchhof P. Differences among western European countries in anticoagulation

management of atrial fibrillation. Data from the PREFER IN AF registry.

Thromb Haemost 2014;111:833–841.

1. O’Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ,

Fonarow GC, Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED,

Piccini JP, Singer DE. Physician practices regarding contraindications to oral anticoagulation

in atrial fibrillation: findings from the Outcomes Registry for Better Informed

Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2014;

167:601–609.e1.

1. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N,

Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation.

Circ Cardiovasc Qual Outcomes 2010;3:624–631.

1. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S,

Miyasato G, Matchar D, Sanchez H. Higher persistence in newly diagnosed

nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Circ Cardiovasc Qual Outcomes 2013;6:567–574.

1. Donze J, Clair C, Hug B, Rodondi N,Waeber G, Cornuz J, Aujesky D. Risk of falls

and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012;125:

773–778.

1. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy

for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med

1999;159:677–685.

1. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA

investigators, Midland Research Practices Network (MidReC).Warfarin versus aspirin

for stroke prevention in an elderly community population with atrial fibrillation

(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a

randomised controlled trial. Lancet 2007;370:493–503.

1. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O’Donnell M,

Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S, AVERROES Steering Committee

and Investigators. Apixaban versus aspirin in patients with atrial fibrillation

and previous stroke or transient ischaemic attack: a predefined subgroup analysis from

AVERROES, a randomised trial. Lancet Neurol 2012;11:225–231

1. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for

predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–

2870.

1. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GYH. The value of the CHA2DS2-VASc score for

refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a

nationwide cohort study. Thromb Haemost 2012;107:1172–1179.

1. Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and

thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart

1. Survey on Atria l Fibrillation. Chest 2010;137:263–272.

Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med

2010;123:484–488.

1. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk

of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093– 1100.

1. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC guidelines for the

management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of

atrial fibrillation. Developed with the special contribution of the European Heart Rhythm

Association. Eur Heart J 2012;33:2719–2747.

1. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral Factor Xa and thrombin inhibitors in the

management of thromboembolism. Annu Rev Med 2011;62:41–57.

1. Lip GYH, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648–661.
2. [Novartis Pharmaceuticals UK Ltd. Sinthrome® (acenocoumarol BP) Summary of Product Characteristics. 2018. Available at: https://www.medicines.org.uk/emc/product/2058 [accessed 20 November 2020].](https://www.medicines.org.uk/emc/product/2058)
3. [Mercury Pharma Group Ltd. Marevan® (Warfarin) Summary of Product Characteristics. 2018. Available at: https://www.medicines.org.uk/emc/product/2803/smpc [accessed 20 November 2020].](https://www.medicines.org.uk/emc/product/2803/smpc)
4. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.
5. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–2104.
6. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.
7. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
8. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875–1876.
9. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med 2014;371:1464–1465.
10. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016;116:754763.
11. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIAAF Investigators. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-TermAntithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J 2018;198:5563.
12. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M,

Turpie AG; XANTUS Investigators. XANTUS: a real-world, prospective, observational

study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:11451153.

1. Martinez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL,

Ziadeh NS, Turpie AGG; XANTUS Investigators. XANTUS-EL: a real-world,

prospective, observational study of patients treated with rivaroxaban for stroke

prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin

America. Egypt Heart J 2018;70:307313.

1. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X,

Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of

apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’

clinical practice. A propensity-matched analysis of 76,940 patients. Thromb

Haemost 2017;117:10721082.

1. Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients

with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol

2018;72:838853.

1. Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marciano I, Mancuso A, Ando G,

Corrao S, Capranzano P, Trifiro G. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol 2018;14:10571069.

1. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP,

Chen TJ, Lip GYH, Chen SA. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018;138:3747.

1. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness

of apixaban versus warfarin in patients with severe renal impairment.

Pharmacotherapy 2017;37:412419.

1. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:15191529.
2. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016;68:25972604.
3. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K

antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:27792790.

1. Verheugt FWA, Gao H, Al Mahmeed W et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J 2018;39:464–473.
2. Active Writing Group of the ACTIVE Investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.
3. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066–2078.
4. Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 2014;7:113–124.
5. The AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002;143:991–1001.
6. Kralev S., Schneider K., Lang S. et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011;6(9):e24964. doi:10.1371/journal.pone.0024964.
7. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962.
8. Beard JR, Officer A, de Carvalho IA et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet 2016;387:2145-2154.
9. Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010;56:1683-1692.
10. Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
11. Buccheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther Adv Cardiovasc Dis 2019;13:1753944719891688.
12. Europace(2021) 00, 1–65 doi:10.1093/europace/euab065
13. Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185–1193.
14. [Yasuda S, Kaikita K, Akao M et al. AFIRE - Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease. European Society of Cardiology Congress. Paris, France, 29 August–2 September 2019. Oral presentaion 3175. Available at: https://svcardiologia.org/es/images/documents/esc2019/AFIRE\_trial\_ESC19.pdf [accessed 27 November 2019].](file://C:\Users\slepa\AppData\Roaming\Microsoft\Word\Yasuda%20S,%20Kaikita%20K,%20Akao%20M%20et%20al.%20AFIRE%20-%20Rivaroxaban%20monotherapy%20versus%20combination%20therapy%20in%20patients%20with%20atrial%20fibrillation%20and%20stable%20coronary%20artery%20disease.%20European%20Society%20of%20Cardiology%20Congress.%20Paris,%20France,%2029%20August–2%20September%202019.%20Oral%20presentaion%203175.%20Available%20at:%20https:\svcardiologia.org\es\images\documents\esc2019\AFIRE_trial_ESC19.pdf%20%5baccessed%2027%20November%202019%5d.)
15. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-34.
16. Lopes RD, Heizer G, Aronson R et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509–1524.
17. 14. Vranckx P, Valgimigli M, Eckardt L et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335–1343.
18. Cannon CP, Bhatt DL, Oldgren J et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–1524.
19. Mega JL, et al. N Engl J Med. 2012;366:9-19.
20. Eikelboom JW,et al. N Engl J Med.2017;377:1319–1330.
21. Gibson CM et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER-AF-PCI). Am Heart J 2015;169:472–478.e5
22. Xarelto Permbledhja e Karakteristikave te Produktit
23. Bayer Yakuhin Ltd. Xarelto (rivaroxaban) Japanese package insert. 2012. Available at: http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000015162.pdf [accessed 10/23/2013].
24. Angiolillo DJ, Goodman SG, Bhatt DL et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation 2018;138:527–536
25. IDF DIABETES ATLAS; 8 edition; <https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html>
26. Decker S (Scripps Whittier Diabetes Institute). Hidden Symptoms of Type 2 Diabetes. (2012) Available at: https://www.scripps.org/news\_items/4260-hidden-symptoms-of-type-2-diabetes [accessed 18 June 2020]
27. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1. Published 2002 Apr 8. doi:10.1186/1475-2840-1-1.
28. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135-S151. doi:10.2337/dc20-S011.
29. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111-S134. doi:10.2337/dc20-S010.
30. Bansilal S, et al. Am Heart J. 2015;170:675–682.e8.
31. Ezekowitz JA, Lewis B, Lopes R et al. Apixaban compared with warfarin in patients with diabetes and nonvalvular atrial fibrillation in the ARISTOTLE trial. J Am Coll Cardiol 2014;63:A372.
32. Brambatti M, Darius H, Oldgren J et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol 2015;196:127–131.
33. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257–e354.
34. Hart RG, Eikelboom JW, Brimble KS et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29:S71–S78.
35. Kimachi M, Furukawa TA, Kimachi K et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev 2017;11:Cd011373.
36. Bassand JP, Accetta G, Al Mahmeed W et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One 2018;13:e0191592.
37. Barrios V, Calderon A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol 2012;65:47–53.
38. Maura G, Billionnet C, Drouin J et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open 2019;9:e026645.
39. Antonucci E, Poli D, Tosetto A et al. The Italian START-register on anticoagulation with focus on atrial fibrillation. PLoS One 2015;10:e0124719.
40. Beyer-Westendorf J, Camm AJ, Fox KAA et al. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thromb J 2019;17:7.
41. Washam JB, Holmes DN, Thomas LE et al. Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from ORBIT-AF. J Am Heart Assoc 2018;7:e008928.
42. Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011;9:1652–1653.
43. Reinecke H, Brand E, Mesters R et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705–711.
44. Echouffo-Tcheugui JB, Shrader P, Thomas L et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. J Am Coll Cardiol 2017;70:1325–1335.
45. Fox K.A.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.
46. Hijazi Z., Hohnloser S.H., Oldgren J. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961–970
47. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30.
48. Hijazi Z, Hohnloser SH, Andersson U et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol 2016;1:451–460.
49. Weir MR, Berger JS, Ashton V et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin 2017;33:1891–1900.
50. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–1393.
51. Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. 2019. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/EPAR\_-\_Product\_Information/human/000829/WC500041059.pdf [accessed 29 August 2019].
52. Daiichi Sankyo Europe GmbH. Lixiana® (edoxaban) Summary of Product Characteristics. 2019. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/EPAR\_-\_Product\_Information/human/002629/WC500189045.pdf [accessed 29 August 2019].
53. Bristol-Myers Squibb, Pfizer. Eliquis® (apixaban) Summary of Product Characteristics. 2019. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/EPAR\_-\_Product\_Information/human/002148/WC500107728.pdf [accessed 29 August 2019].
54. Olesen JB, Lip GYH, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625–635.
55. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
56. Olesen JB, Lip GYH, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625–635.
57. Roldan V, Marín F, Fernández H et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111:1159–1164.
58. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629–636.
59. Turakhia MP, Blankestijn PJ, Carrero JJ et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018;39:2314–2325.
60. Bansal N, Xie D, Tao K et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol 2016;11:1189–1196.
61. Posch F, Ay C, Stoger H et al. Exposure to vitamin K antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost 2019;3:207–216.
62. Wheeler D, Giugliano R, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost 2016;14:461–467.
63. Hemmelgarn BR, et al. Kidney Int. 2006;69:2155–2161.
64. Stroke Risk in Atrial Fibrillation Working Group. Neurology 2007;69:546‒554
65. Ashburner JM, Go AS, Chang Y et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. J Am Coll Cardiol 2016;67:239–247.
66. BK, Yatsuya H, Matsushita K et al. Association of kidney disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective community-based cohorts. Stroke 2014;45:1925–1931.
67. [The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–554.](http://www.ncbi.nlm.nih.gov/pubmed/17679673)
68. Yao X., Tangri N., Gersh B.J. et al. Renal outcomes in anticoagulated patients with atrial fibrillation/Suplementary Material. J Am Coll Cardiol. 2017;70(21):2621–2632.
69. Coleman CI, Kreutz R, Sood NA et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med 2019;132:1078–1083.
70. Coleman CI, Kreutz R, Sood N et al. Rivaroxaban's impact on renal decline in patients with nonvalvular atrial fibrillation: A US MarketScan claims database analysis. Clin Appl Thromb Hemost 2019;25:1076029619868535..
71. [Vaitsiakhovich T, Coleman CI, Kleinjung F et al. Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims. European Society of Cardiology Congress. Paris, France, 31 August–5 September 2019, Poster P4746. Available at: https://academic.oup.com/eurheartj/article-abstract/40/Supplement\_1/ehz745.1122/5596296?redirectedFrom=fulltext [accessed 28 February 2020].](https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz745.1122/5596296?redirectedFrom=fulltext)
72. [Bonnemeier H, Kreutz R, Kloss S et al. Comparative safety and effectiveness of non-vitamin-K oral anticoagulants vs phenprocoumon in patients with non-valvular atrial fibrillation and diabetes - results from the RELOADED study. 5th European Stroke Organisation Conference. Milan, Italy, 22–24 May 2019, AS25-066. Available at: https://journals.sagepub.com/toc/esoa/4/1\_suppl [accessed 16 August 2019].](https://journals.sagepub.com/toc/esoa/4/1_suppl)
73. Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial Fibrillation in Older People: Concepts and Controversies. Frontiers in medicine 2019;6:175.
74. Zvan Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009;40:1410-1416.
75. Patti G, Lucerna M, Pecen L et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc 2017;6:e005657.
76. Madhavan M, Holmes DN, Piccini JP et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J 2019;211:77-89
77. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016;388:806-817.
78. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130:138–146.
79. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864–1872.
80. Lauw MN, Eikelboom JW, Coppens M et al. Effects of dabigatran according to age in atrial fibrillation. Heart 2017;103:1015–1023.
81. Kato ET, Giugliano RP, Ruff CT et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016;5:e003432.
82. Hanon O, Chaussade E, David JP et al. SAFIR cohort: One-year prospective follow-up of very old and frail patients treated with direct oral anticoagulant, rivaroxaban. Arch Cardiovasc Dis Suppl 2020;12:115.
83. Patti G, Pecen L, Lucerna M et al. Net clinical benefit of non-vitamin K antagonist vs vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med 2019;132:749–757.
84. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc 2018;7.
85. Beyer-Westendorf J, Kreutz R, Posch F, Ay C. The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol 2018;253:71-77.
86. Pikija S, Sztriha LK, Sebastian Mutzenbach J, Golaszewski SM, Sellner J.

Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving

alteplase: a systematic review of the available evidence. CNS Drugs

2017;31:747757.

1. Hart RG, Sharma M, Mundl H, et al. NAVIGATE ESUS

Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of

Undetermined Source. N Engl J Med 2018;378:21912201.

1. Diener HC, Sacco RL, Easton JD, et al; RESPECT

ESUS Steering Committee Investigators. Dabigatran for prevention of

stroke after embolic stroke of undetermined source. N Engl J Med

2019;380:19061917.

1. Li Y-G, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, Wang

Y-T, Lip GYH, Fauchier L. C2HEST score and prediction of incident atrial

fibrillation in poststroke patients: a French nationwide study. J Am Heart Assoc

2019;8:e012546.

1. Wilson D, Ambler G, Lee KJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol 2019;18:653665.
2. Murthy SB, Gupta A, Merkler AE, Navi BB, Mandava P, Iadecola C, Sheth KN,

Hanley DF, Ziai WC, Kamel H. Restarting anticoagulant therapy after intracranial

hemorrhage: a systematic review and meta-analysis. Stroke

2017;48:15941600.

1. Hankey G.J. et al. Rivaroxaban compared ëith ëarfarin in patients ëith atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315–22
2. Coleman C.I. et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017; doi:10.1161/ STROKEAHA.117.017474.
3. Collings SL, Lefevre C, Johnson ME et al. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. PLoS One 2017;12:e0185642.
4. Laakso M. Diabetes Care. 2010;33:442–449.
5. Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes 2014;5:835-846